Esomeprazole, a new proton pump inhibitor, is the S - isomer of omeprazole.
艾司奥美拉唑是一种新型的质子泵抑制剂， 它是奥美拉唑的S-型光学异构体。
Conclusion The PPI esomeprazole has no significant influence on inhibition of platelet aggregation by clopidogrel.
结论未发现埃索美拉唑对氯吡格雷的抗血小板聚集作用产生明显影响。
Objective to observe the influence of proton pump inhibitor (PPI) esomeprazole on antiplatelet effect of clopidogrel.
目的观察质子泵抑制剂埃索美拉唑是否影响氯吡格雷的抗血小板聚集作用。
Esomeprazole is a new member of proton pump inhibitors (PPI) with strong suppressive effects on gastric acid secretion.
埃索美拉唑是新一代质子泵抑制剂成员，有较强的抑制胃酸分泌效应。
RESULTS: The cost-effectiveness ratio and incremental cost - effectiveness ratio of Esomeprazole were higher than those of omeprazole.
结果埃索美拉唑的成本、效果比和增长的成本、效果比均高于奥美拉唑。
Conclusion We did not find the difference between the two CYP2C19 phenotypes in relation to the acid-suppressing effect of esomeprazole.
结论未观察到CYP2C19基因多态性对埃索美拉唑的抑酸效应的影响。
CONCLUSION: Clinicians should tighten monitoring on the application of esomeprazole to reduce the occurrence of esomeprazole-induced ADR.
结论：临床上应加强埃索美拉唑合理应用的监测，以减少不良反应的发生。
Buffered esomeprazole (BE) is an oral preparation consisting of an inner core of non-enteric-coated esomeprazole with a shell of sodium bicarbonate.
埃索美拉唑缓释剂(BE)是由碳酸氢钠包被非肠溶性埃索美拉唑组成的口服制剂。
METHODS: Esomeprazole and omeprazole for treatment and maintenance treatment of reflux oesophagitis was analyzed by using the cost-effectiveness analytical method.
方法对埃索美拉唑、奥美拉唑治疗反流性食管炎及治愈后维持方案进行成本-效果分析。
Methods 100 Chinese patients that taking long term esomeprazole magnesium were choosed and randomized into 3 groups, and 30 normal Chinese were choosed as the controls.
方法选取长期服用埃索美拉唑镁片患者100例，根据服用时间长短随机分为3组，另选30例胃镜检查正常者作为正常对照组。
Methods 100 Chinese patients that taking long term esomeprazole magnesium were choosed and randomized into 3 groups, and 30 normal Chinese were choosed as the controls.
方法选取长期服用埃索美拉唑镁片患者100例，根据服用时间长短随机分为3组，另选30例胃镜检查正常者作为正常对照组。
应用推荐